.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,393,543

« Back to Dashboard

Claims for Patent: 7,393,543

Title:Vaginally administratable progesterone-containing tablets and method for preparing same
Abstract:The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the wetted, micronized progesterone; mixing the dry micronized progesterone with other pharmaceutically acceptable excipients or diluents; and; forming a tablet by direct compaction of the dry micronized progesterone. Tablets prepared by this method are also provided.
Inventor(s): Jossifoff; Azariah (Ramat Gan, IL)
Assignee: Ferring B.V. (Hoofddorp, NL)
Application Number:10/832,742
Patent Claims: 1. A pharmaceutical tablet consisting of dry natural progesterone as an active ingredient, pharmaceutically acceptable excipients, and an effervescent, which tablet dissolves after placement in the vagina and provides a T.sub.max from 3.05 hours to 9.75 hours after said tablet is placed in the vagina.

2. A tablet for vaginal administration consisting of natural progesterone, an effervescent, and pharmaceutically acceptable excipients, and prepared by the steps of: (i) preparing a mixture consisting of water and the natural progesterone to obtain wetted natural progesterone; and drying said wetted natural progesterone to obtain dry natural progesterone; (ii) mixing said dry natural progesterone with at least one pharmaceutically acceptable excipient and an effervescent to form a second mixture; and (iii) forming a dry tablet by direct compaction of said second mixture said tablet having the property of dissolving in the vagina and providing a T.sub.max from 3.05 hours to 9.75 hours after said tablet is placed in the vagina.

3. A vaginal tablet consisting of natural progesterone, an effervescent, and pharmaceutically acceptable excipients, and prepared by the steps of: (i) mixing water with the natural progesterone to obtain wetted natural progesterone in the absence of a pharmaceutically acceptable excipients; and drying said wetted natural progesterone to form dry natural progesterone; (ii) mixing said dry natural progesterone with (a) pharmaceutically acceptable excipients and (b) an effervescent to form a mixture; and (iii) forming said tablet in dry form by direct compaction of said mixture, the tablet dissolving in the vagina and providing a T.sub.max from 3.05 hours to 9.75 hours after said tablet is placed in the vagina.

4. A vaginal tablet sing consisting of between about 6 to 20 wt. % dry natural progesterone, between about 5 to 12 wt. % effervescent, and pharmaceutically acceptable excipients, the tablet dissolving upon placement in the vagina and providing a T.sub.max from 3.05 hours to 9.75 hours after said tablet is placed in the vagina.

5. A tablet according to claim 4, wherein the progesterone in said tablet is present in an amount of between about 8 to 12 wt. %.

6. A tablet according to claim 5, wherein the effervescent in said tablet is present in an amount of between about 6 to 8 wt. %.

7. The tablet of claim 1, wherein the progesterone is micronized progesterone.

8. The tablet of claim 2, wherein the progesterone is micronized progesterone.

9. The tablet of claim 3, wherein the progesterone is micronized progesterone.

10. The tablet of claim 4, wherein the progesterone is micronized progesterone.

11. The tablet of claim 7, wherein the micronized progesterone in said tablet is present in an amount of at least 50 mg.

12. The tablet of claim 7, wherein the micronized progesterone in said tablet is present in an amount of about 50 mg.

13. The tablet of claim 7, wherein the micronized progesterone in said tablet is present in an amount of about 100 mg.

14. The tablet of claim 10, wherein the micronized progesterone in said tablet is present in an amount of at least 50 mg.

15. The tablet of claim 10, wherein the micronized progesterone in said tablet is present in an amount of about 50 mg.

16. The tablet of claim 10, wherein the micronized progesterone in said tablet is present in an amount of about 100 mg.

17. The tablet of claim 1, wherein the effervescent in said tablet is present in an amount of from about 5% to about 12% by weight.

18. The tablet of claim 1, wherein the effervescent in said tablet is present in an amount of about 8% by weight.

19. The tablet of claim 4, wherein the effervescent in said tablet is present in an amount of from about 5% to about 12% by weight.

20. The tablet of claim 4, wherein the effervescent in said tablet is present in an amount of about 8% by weight.

21. A vaginally administrable tablet consisting of dry micronized natural progesterone as an active ingredient, pharmaceutically acceptable excipients and an effervescent, wherein said tablet has the property of dissolving in the vagina and providing a T.sub.max from 3.05 hours to 9.75 hours after said tablet is placed in the vagina.

22. A vaginal tablet consisting essentially of dry micronized natural progesterone, colloidal anhydrous silica, maize 1500 starch, povidone 30, lactose, adipic acid, sodium bicarbonate, magnesium stearate, and sodium lauryl sulfate, wherein the tablet has the property of dissolving upon placement in the vagina.

23. The tablet of claim 22, consisting essentially of 8 wt. % dry micronized natural progesterone, 0.2 wt. % colloidal anhydrous silica, 16.8 wt. % maize 1500 starch, 3.9 wt. % povidone 30, 60.8 wt. % lactose, 4.6 wt. % adipic acid, 3.4 wt. % sodium bicarbonate, 1.8 wt. % magnesium stearate, and 60.4 wt. % sodium lauryl sulfate.

24. A vaginal tablet consisting of dry micronized natural progesterone as an active ingredient, pharmaceutically acceptable excipients, and an effervescent.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc